

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

EDITORIAL

Controlling Antimicrobial-Resistant Pathogens

WILLIAM R. JARVIS, MD

369

ORIGINAL ARTICLES

Increased Susceptibility to Vancomycin-Resistant *Enterococcus* Intestinal Colonization Persists After Completion of Anti-Anaerobic Antibiotic Treatment in Mice

USHA STIEFEL, MD; NICOLE J. PULTZ, BS; MARION S. HELFAND, MD, MS; CURTIS J. DONSKY, MD

373

Effect of the Increasing Use of Piperacillin/Tazobactam on the Incidence of Vancomycin-Resistant Enterococci in Four Academic Medical Centers

USHA STIEFEL, MD; DAVID L. PATERSON, MD; NICOLE J. PULTZ, BS; STEVEN M. GORDON, MD; DAVID C. ARON, MD, MS; CURTIS J. DONSKY, MD

380

Eradication of a Large Outbreak of a Single Strain of vanB Vancomycin-Resistant *Enterococcus faecium* at a Major Australian Teaching Hospital

KERYN J. CHRISTIANSEN, MBBS, FRCPA; PATRICIA A. TIBBETT, RN, BAppSc; WILLIAM BERESFORD, MBChB, FAFPHM; JOHN W. PEARMAN, MD, FRCPA; ROSIE C. LEE, RN, BNSG; GEOFFREY W. COOMBS, BAppSc; IAN D. KAY, BAppSc; FRANCES G. O'BRIEN, BAppSc; SILVANO PALLADINO, BAppSc, MHTMgt; CHARLES R. DOUGLAS, MBBS, FAFPHM; PHILIP D. MONTGOMERY, MBBS, FRACMA; TERRI ORRELL, RN, BNSG; ALLISON M. PETERSON, RN, BNSG; FRANK P. KOSARAS, BAppSc; JAMES P. FLEXMAN, PhD, FRCPA; CHRISTOPHER H. HEATH, FRCPA, FRACP; CHERYLL A. MCCULLOUGH, BAppSc

384

Impact of Surveillance for Vancomycin-Resistant Enterococci on Controlling a Bloodstream Outbreak Among Patients With Hematologic Malignancy

RAY HACHEM, MD; LINDA GRAVISS, MT(ASCP), CIC; HEND HANNA, MD; REBECCA ARBUCKLE, MS; TANYA DVORAK, BS; BRENDA HACKETT, MPH, CIC; VIRGINIA GONZALEZ, BS, CIC; CHERYL PEREGO, MPH, CIC; JEFFREY TARRAND, MD; ISSAM RAAD, MD

391

Do Infection Control Measures Work for Methicillin-Resistant *Staphylococcus aureus*?

JOHN M. BOYCE, MD; NANCY L. HAVILL, MT; CYNTHIA KOHAN, MT, MS; DIANE G. DUMIGAN, RN, BSN; CATHERINE E. LIGI, RN, BSN

395

Intervention to Reduce the Incidence of Methicillin-Resistant *Staphylococcus aureus* Skin Infections in a Correctional Facility in Georgia

SUSAN H. WOOTTON, MD; KATHRYN ARNOLD, MD; HOLLY A. HILL, MD, PhD; SIGRID McALLISTER, BS, MT(ASCP); MARSHA RAY, MS; MOLLY KELLUM, BS; MADIE LAMARRE, MSN, CFNP; MARY ELLEN LANE, RN, MBA; JASMINE CHAITRAM, MPH; SUSAN LANCE-PARKER, DVM, PhD; MATTHEW J. KUEHNERT, MD

402

Emergence of Vancomycin-Resistant Enterococci in San Francisco Bay Area Hospitals During 1994 to 1998

JON ROSENBERG, MD; WILLIAM R. JARVIS, MD; SHARON L. ABBOTT, MS; DUC J. VUGIA, MD, MPH, FOR THE CALIFORNIA EMERGING INFECTIONS PROGRAM

408

Failure to Develop Vancomycin-Resistant *Enterococcus* With Oral Vancomycin Treatment of *Clostridium difficile*

CASSANDRA D. SALGADO, MD, MS; EVE T. GIANNETTA, RN; BARRY M. FARR, MD, MSc

413

A Cost-Benefit Analysis of Gown Use in Controlling Vancomycin-Resistant *Enterococcus* Transmission: Is It Worth the Price?

LAURA A. PUZNIAK, PhD; KATHLEEN N. GILLESPIE, PhD; TERRY LEET, PhD; MARIN KOLLEF, MD; LINDA M. MUNDY, MD

418

Continued inside.

MRSA may be resistant to antibiotics.
But it's not resistant to genetic detection.

IDI-MRSA™ - The only FDA-cleared, real-time molecular test for MRSA, exclusively on the Cepheid SmartCycler® System.

IDI-MRSA™ is a rapid, highly sensitive test that specifically detects methicillin-resistant *Staphylococcus aureus* directly from a single nasal swab specimen – in less than two hours. The speed and simplicity of IDI-MRSA make it ideal for asymptomatic MRSA testing, providing rapid results that help prevent and control the spread of MRSA. The IDI-MRSA test is designed specifically for use on the Cepheid SmartCycler® System.

www.cepheid.com

IDI-MRSA®

Practice of the patented polymerase chain reaction (PCR) process requires a license. The SmartCycler® is an Authorized Thermal Cycler and may be used with PCR licenses available from Applied Biosystems. Its use with Authorized Reagents also provides a limited PCR license in accordance with the label rights accompanying such reagents. Purchase of this instrument does not convey any right to practice the 5' nuclease assay or any of the other real-time methods covered by patents owned or controlled by Roche or Applied Biosystems.



Sample in. Answer out.™

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

CONTENTS

Continued from cover

ORIGINAL ARTICLES

- Risk Factors and Costs Associated With Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections**
CAROLYN GUERTIN MCHUGH, MPH; LEE W. RILEY, MD 425
- Emergence of Resistant Staphylococci on the Hands of New Graduate Nurses**
JEANNIE P. CIMIOTTI, RN, MS; FANN WU, MD, PhD; PHYLLIS DELLA-LATTA, PhD; MIRJANA NESIN, MD;
ELAINE LARSON, RN, PhD 431

CONCISE COMMUNICATIONS

- Control of Nosocomial Acquisition of Vancomycin-Resistant *Enterococcus* Through Active Surveillance of Hemodialysis Patients**
R. NEAL AXON, MD; JOHN J. ENGEMANN, MD; JAMES BUTCHER, RN; KATHY LOCKAMY, RN; KEITH S. KAYE, MD, MPH 436
- Prevalence of and Risk Factors for Nasal Colonization With *Staphylococcus aureus* Among Human Immunodeficiency Virus-Positive Outpatients in Singapore**
J. S. VILLACIAN, MD; T. BARKHAM, MD; A. EARNEST, MSc; N. I. PATON, MD 438

LETTERS TO THE EDITOR

- Is Methicillin-Resistant *Staphylococcus aureus* More Contagious Than Methicillin-Susceptible *S. aureus* in a Surgical Intensive Care Unit?**
PAUL J. DRINKA, MD; MARY E. STEMPEL, MT(ASCP), MS; CATHY D. GAUERKE, MT(ASCP); JANICE M. MILLER, MT(ASCP);
KURT D. REED, MD 363
- Is Nasal Carriage of Methicillin-Resistant *Staphylococcus aureus* More Prevalent Among Student Healthcare Workers?**
PHILIPPE BERTHELOT, MD, MPH, PhD; FLORENCE GRATTARD, MD, PhD; PASCAL FASCIA, MD; ISABELLE MARTIN, MD;
FRANCK OLIVIER MALLAVAL, MD; ALAIN ROS, MD; BRUNO POZZETTO, MD, PhD; FREDERIC LUCHT, MD 364
- Resistance to Penicillin and Erythromycin in Viridans Streptococcal Bloodstream Isolates From Cancer and Non-Cancer Patients Within 10 Years**
ADRIANA ONDRUSOVA, MD; ANNE LISKOVA, MD; JOSEPH MIKLOSKO, MD; ROBERTA BABELA, PhD; VLADIMIR KRČMERY, FACP, MD 365

Full-text articles available online at ICHEJournal.com

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0195-9417, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Road, Thorofare, NJ 08086. Telephone: (856) 848-1000.

SHEA: 66 Canal Center Plaza, Suite 600, Alexandria, VA 22314; telephone, 703-299-0200; fax, 703-299-0204; e-mail address, info@shea-online.org.

COPYRIGHT 2004 The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$139.00; Two years-\$199.00; Three years-\$259.00; Institutional: One year-\$269.00; Two years-\$459.00; Three years-\$639.00. Fellows: \$54.50 per year with proof of training status. Canada: add 7% Goods & Services tax; Overseas: add \$49.00 each year for delivery by air service. Single copies of current issues may be obtained for \$24.00.

INSTRUCTIONS TO AUTHORS: Authors may submit electronic versions of their manuscripts prepared in accordance with the 2001 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." An electronic version is available at www.icmje.org. Submit to RapidReview.com. All submissions must be accompanied by copyright form(s) signed by all authors.

REPRINTS: All requests to reprint or use material published herein should be addressed to John Kain, SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086. For reprint orders and prices, contact John Kain at (856) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$20 per page is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923; phone (978) 750-8400. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANGE OF ADDRESS: Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and Rndex Top 100.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

EDITORIAL ADVISORY BOARD

EDITORIAL OFFICE

SLACK Incorporated
6900 Grove Road
Thorofare, NJ 08086
(856) 848-1000; (856) 848-6091 (FAX)
E-mail: iche@slackinc.com

EDITOR

Barry M. Farr, MD, MSc

DEPUTY EDITORS

David P. Calfee, MD, MS

William R. Jarvis, MD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS

Beyond Infection Control:

The New Hospital Epidemiology

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Infections in Immunocompromised

Patients

Kent Sepkowitz, MD

New York City, New York

Information Management

John A. Sellick, DO

Amherst, New York

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

- | | |
|---------------------------------|------------------------------------|
| J. Wesley Alexander, MD | Cincinnati, Ohio |
| Miriam Alter, PhD | Atlanta, Georgia |
| Hilary Babcock, MD | St. Louis, Missouri |
| Elise M. Beltrami, MD, MPH | Decatur, Georgia |
| Richard E. Besser, MD | Atlanta, Georgia |
| Marc J. M. Bonten, MD, PhD | Utrecht, The Netherlands |
| John M. Boyce, MD | New Haven, Connecticut |
| Christian Brun-Buisson, MD | Creteil, France |
| John P. Burke, MD | Salt Lake City, Utah |
| Yehuda Carmeli, MD, MPH | Tel Aviv, Israel |
| Carol Chenoweth, MD | Ann Arbor, Michigan |
| Sara E. Cosgrove, MD, MS | Baltimore, Maryland |
| Donald E. Craven, MD | Burlington, Massachusetts |
| Erika D'Agata, MD, MPH | Boston, Massachusetts |
| Franz Daschner, MD | Freiburg, Germany |
| Patch Dellinger, MD | Seattle, Washington |
| Charles E. Edmiston, Jr., PhD | Milwaukee, Wisconsin |
| Theodore C. Eickhoff, MD | Denver, Colorado |
| Jean Yves Fagon, MD, MPH | Paris, France |
| Mark Farrington, MA, FRCPath | Cambridge, England, United Kingdom |
| Victoria J. Fraser, MD | St. Louis, Missouri |
| Richard A. Garibaldi, MD | Farmington, Connecticut |
| Petra Gastmeier, MD | Hanover, Germany |
| Dale N. Gerding, MD | Hines, Illinois |
| Stephan Harbarth, MD, MS | Geneva, Switzerland |
| Anthony D. Harris, MD, MPH | Baltimore, Maryland |
| David K. Henderson, MD | Bethesda, Maryland |
| Peter N.R. Heseltine, MD | San Juan, California |
| Karen Hoffmann, RN, CIC, MS | Chapel Hill, North Carolina |
| Janine Jagger, MPH, PhD | Charlottesville, Virginia |
| John A. Jernigan, MD, MS | Atlanta, Georgia |
| Jacob L. Kool, MD, PhD | Fort Collins, Colorado |
| Ebbing Lautenbach, MD, MPH | Philadelphia, Pennsylvania |
| Allison McGeer, MD | Toronto, Ontario, Canada |
| John E. McGowan, Jr., MD | Atlanta, Georgia |
| Leonard A. Mermel, DO, ScM | Providence, Rhode Island |
| Robert R. Muder, MD | Pittsburgh, Pennsylvania |
| Carlene A. Muto, MD, MS | Pittsburgh, Pennsylvania |
| Joseph M. Mylotte, MD, CIC | Buffalo, New York |
| Lindsay Nicolle, MD | Winnipeg, Manitoba, Canada |
| Juhani Ojajarvi, MD | Helsinki, Finland |
| Michael T. Osterholm, PhD, MPH | Minneapolis, Minnesota |
| David L. Paterson, MBBS, FRACP | Pittsburgh, Pennsylvania |
| Jan Evans Patterson, MD | San Antonio, Texas |
| Sindy M. Paul, MD | Yardley, Pennsylvania |
| David A. Pegues, MD | Los Angeles, California |
| Michael A. Pfaller, MD | Iowa City, Iowa |
| Samuel Ponce de Leon, MD, MSc | Mexico City, Mexico |
| Isaam Raad, MD | Houston, Texas |
| Jordi Rello, MD, PhD | Tarragona, Spain |
| Manfred L. Rotter, MD, DipBact | Vienna, Austria |
| Henning Rüden, MD | Berlin, Germany |
| Lisa Saiman, MD, MPH | New York, New York |
| Syed A. Sattar, PhD | Ottawa, Ontario, Canada |
| William E. Scheckler, MD | Madison, Wisconsin |
| Lynne M. Sehulster, PhD | Atlanta, Georgia |
| Andrew E. Simor, MD | Toronto, Ontario, Canada |
| Denis W. Spelman, FRACP | Melbourne, Victoria, Australia |
| V. Susan Springthorpe, BSc, MSc | Ottawa, Ontario, Canada |
| Jeffrey R. Starke, MD | Houston, Texas |
| Janet E. Stout, PhD | Pittsburgh, Pennsylvania |
| Clyde Thornsberrry, PhD | Franklin, Tennessee |
| Jerome Tokars, MD, MPH | Atlanta, Georgia |
| Timothy R. Townsend, MD | Baltimore, Maryland |
| Antoni Trilla, MD, PhD | Barcelona, Spain |
| Robert A. Weinstein, MD | Chicago, Illinois |
| Sergio B. Wey, MD | São Paulo, Brazil |

SLACK Incorporated, 6900 Grove Road, Thorofare, New Jersey 08086. (856) 848-1000



Executive Vice President

Richard N. Roash

Vice President, Publishing Operations

John C. Carter

Editorial Director

Jennifer Kilpatrick

Executive Editor

Shirley P. Strunk, ELS

Assistant Editor

Jaime Underwood

Circulation Manager

Lester J. Robeson, CCCP

Production Director

Christine Malin

Vice President, U.S. Advertising

Wayne McCourt

Director of Association Services

Kathy Huntley

Advertising Sales Representative

Scotty Turner

Advertising Sales Administrator

Joanne Patterson

Sales Director, Classified/Recruitment


Kristy Irwin

Classified/Recruitment Sales


Anabella O'Brien

Director of Reprint Sales

John Kain



Kill.



**Keep
killing.**

**For immediate and persistent antiseptic activity,
you're in the clear with Hibistat® and Hibiclens®.**

Clinical studies* have proven the efficacy and persistence of Hibistat® and Hibiclens®, demonstrating both antiseptics go to work on germs in seconds, and have a cumulative effect that continues to kill germs long after your shift is over.

*In the most recent study, a novel demonstration was developed to prove their antiseptic persistence. The study consisted of using agar plates that were inoculated with staph aureus. Hands were either rinsed or washed with Hibistat® or Hibiclens®, and then pressed onto the inoculated plates – palms down. The plates were then incubated and a whitish film of staph aureus grew in areas **not** affected by antiseptic activity.*



HIBISTAT®
Healthcare Personnel Hand Antiseptic

Plates touched by Hibistat® showed immediate kill, displaying a clear, darker-colored handprint on areas affected by the antiseptic rinse. Hibistat®, with its alcohol + chlorhexidine gluconate (CHG) formulation, went to work on contact and showed persistence after only one hand rinse, making it an ideal, portable companion when regular handwashing is not an option.**

Hibiclens®, armed with its 4% Hibitane® (CHG) formulation, killed immediately and displayed a cumulative effect that didn't know when to quit. In fact, this demonstration showed the antiseptic still killing on the fifth day of use and 6 hours after the final daily hand wash.***



HIBICLENS®
Antiseptic / Antimicrobial Skin Cleanser

**Immediately kill and keep killing germs with Hibistat® and Hibiclens®.
For more information about Hibistat® or Hibiclens®, call 1-800-843-8497.**

*Test on file.

**Left photo - The darker color in the handprint shows the immediate effect of Hibistat® on staph aureus.

***Right photo - The darker color in the handprint shows the cumulative effect of Hibiclens® on staph aureus the 5th day of use, 6 hours after the final daily hand wash.

The persistence of Hibistat® and Hibiclens® provides extra protection. Recommended antiseptic procedures of your institution should be followed when using either of these antiseptics.

REGENT

From the makers of Hibiclens® and Biogel®, www.regentmedical.com. Regent, Biogel, Hibiclens, Hibistat, Regent logo, Biogel logo, Hibiclens logo, and Hibistat logo are trade marks of the SSL group. Distributed by Regent Medical, Norcross, GA 30092. ©2004 Regent Medical. All rights reserved.

INFECTIOUS DISEASE

Allegheny General Hospital is recruiting an individual for a full-time position in Infectious Diseases. Primary responsibilities will be in Infection Control and Hospital Epidemiology. Prior experience in this area is preferred. Other responsibilities will encompass inpatient and outpatient consultative infectious disease practice, including HIV medicine at our Ryan White funded HIV/AIDS clinic. A strong commitment to the clinical teaching of medical students and residents is required. Academic rank will be based on qualifications, with a faculty appointment with the Drexel University College of Medicine. Applicants must be board certified or board eligible in Infectious Diseases. Please send your CV and cover letter to: **Richard P. Shannon, MD, Chairman, Department of Medicine, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA, 15212** or Email to rshannon@wpahs.org



Sign up

for the

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY News Wire

An easy-to-use source for the busy infection control professional! Get the latest headlines from the authority in infection control and hospital epidemiology – sent right to your computer.

Register today for the FREE, monthly e-mail news wire, featuring headlines from:

- Original, peer-reviewed scientific articles
- Articles written and edited by the foremost experts in infection control and epidemiology
- News from the Society for Healthcare Epidemiology of America

SHEA Members, you're already eligible:

The News Wire provides Society for Healthcare Epidemiology of America members and INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY journal subscribers with direct links to the latest articles.

Not a member or subscriber? Register today for the News Wire and see what you've been missing.

Sign up at www.ICHEJournal.com

A SLACK Incorporated® Publication

The Official Journal of The Society for Healthcare Epidemiology of America

INFECTION CONTROL AND
HOSPITAL EPIDEMIOLOGY

EpiQuest®

“Making Time for Prevention”

THE Healthcare Epidemiology Software!

EpiQuest® is for Safe Environment Challenges; Infection Surveillance, Prevention & Control; Data Import-Export; Resistant Organism; Antibiotic Use; Outbreak Management, and Bioterrorism. Organize, Analyze, Graph, Benchmark internally & externally with CDC NNIS 12/03 data, and Report. EpiQuest® is for all care levels in PC/Tablet /LAN/WAN/Wireless or Cable. WIZARD helps plus queries across healthcare encounters. Meet JCAHO 2004-5 Standards using EpiQuest®. “Referred to Root Cause Analysis” can be in Actions and Outcomes of Incidents for analysis and reporting.

News Flash from London: Health Protection Agency (HPA), Center for Disease Surveillance & Control (CDSC) with Department of Health (DOH) announces the ASEPTIC (“A Systems Evaluation Project for Infection Control”) three programs to meet criteria for implementation in England. EpiQuest finished first in overall evaluator scores, the only North American software program to meet the evaluation standards, and the choice for installation in some of the most prestigious UK teaching hospitals. Steve Streed, MS, CIC, EpiQuest VP is spearheading implementation via EpiQuest Europe based in Cambridge, England.

EpiQuest® is embedded in SYBASE®.

www.epiquest.com Phone: 305 853 5574 epiquest@bellsouth.net; bonniet@epiquest.com **EpiQuest® LLC**
www.epiquesteurope.com Tel: (0) 1480 862 080 howardt@oraldent.co.uk; SteveStreed@oraldent.co.uk **EpiQuest Europe Ltd**
EpiQuest® is copyrighted, trademarked in the United States of America, Canada, United Kingdom, Commonwealth & Australia.

**GIVE ME
FIVE.**

**STREPTOCOCCUS.
MRSA.
STAPHYLOCOCCUS.
E. COLI.
VRE.**

Never fear. PURELL® kills 99.99% of most common germs that may cause illness, like MRSA. And the CDC says



eliminating germs on hands is the single most important factor in preventing the spread of dangerous germs.

Powerful defense against germs.

5-way infection control in one complete system

Only the Bardex® I.C. Complete Care™ Infection Control Foley Catheter* System including Bacti-Guard®* silver alloy coating^{1,2,3} offers complete infection control to address the 5 risk areas during catheterization.

1 Reduce risks while catheter is indwelling^{1,2,3}

2 Minimizes infection risk at the catheter-tubing junction

3 Repels bacteria and yeasts during drainage

4 Protects against retrograde bacterial migration at the outlet

5 Resists pathogen colonization at collection

Find out more about the Bardex® I.C. Complete Care™ Infection Control Foley Catheter* System.

Call 800-526-4455.

www.bardmedical.com

BARDD

1. Maki DG, Tambyah PA. Engineering out the risk of infection with urinary catheters. *Emer Infect Dis.* 2001;7:342-347.

2. Karchmer TB, Giannetta ET, Muto CA, Strain BA, Farr BM. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. *Arch Int Med.* 2000;160:3294-3298.

3. Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection. *Arch Int Med.* 2000;160:2670-2675.

Please consult product label and insert for any indications, contraindications, hazards, warnings, cautions and directions for use. *The Foley catheters included in the Bardex I.C. Complete Care System contain Bacti-Guard® silver alloy coating, which is licensed from Adhesive Technology (International) Licensing, B.V. Bard and Bardex are registered trademarks of C.R. Bard, Inc., or an affiliate. The I.C. logo and Complete Care are trademarks of C.R. Bard, Inc., or an affiliate. Bacti-Guard is a registered trademark of Adhesive Technology (International) Licensing, B.V. ©2004 C.R. Bard, Inc. All Rights Reserved.